Eurofins Scientific SE · EURONEXT:ERF

Eurofins Scientific — Debt Investor Presentation (May 2021)

47 slides from Eurofins Scientific's debt investor presentation, May 10, 2021

  1. Slide 1: Credit Presentation

    CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af

  2. Slide 2: Disclaimer

    Disclaimer This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on

  3. Slide 3: Agenda

    Agenda I. Eurofins at a glance II. Market & Strategic Positioning III. Commitment to ESG IV. Finance & Outlook V. Contemplated transaction CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an auth

  4. Slide 4: I. Eurofins at a glance

    I. Eurofins at a glance CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 4

  5. Slide 5: Key operational highlights

    Key operational highlights • Eurofins remained very active in fighting the pandemic throughout Q1 2021: ➢ Set up very high throughput SARS-CoV-2 NGS1 capacity and won large contracts to support several countries and institutions to monitor and identify the emergence and spread of new Variants of Int

  6. Slide 6: Eurofins' Mission is to contribute to global Health, Safety & Environment

    Eurofins’ Mission is to contribute to global Health, Safety & Environment with the best in bioanalysis Eurofins provides testing services in ▪ Founded in 1987 four main areas that have a strong ▪ IPO on 24 October 1997 at €0.183 impact on human health ▪ Eurofins’ share price has multiplied by 375 ti

  7. Slide 7: Leading global and local market positions in attractive high-growth markets (1/2)

    Leading global and local market positions in attractive high-growth markets* (1/2) Testing for Food & Feed Testing Environment Testing Clinical Diagnostics Pharma/Biotech/Agrosciences N°1 to N°3* N°1* N°1* Eurofins position Start-Up worldwide worldwide worldwide Start 2014 Start 2000-2005 Start 1987

  8. Slide 8: Leading global and local market positions in attractive high-growth markets (2/2)

    Leading global and local market positions in attractive high-growth markets* (2/2) Testing for Food & Feed Testing Environment Testing Clinical Diagnostics Pharma/Biotech/Agrosciences N°1 to N°3* N°1* Eurofins N°1* Start-Up worldwide worldwide position worldwide Start 2014 Start 2000-2005 Start 1987

  9. Slide 9: Building the Platform – Eurofins 2012 - Eurofins 2020

    Building the Platform – Eurofins 2012 - Eurofins 2020 Progress to Date 2012-2020 ∆ 2012 2015 2019 2020 +8 years Revenues (€ m) 1,044 1,950 4,563 5,439 23% CAGR Employees 10,890 18,382 43,320 50,000 21% CAGR (average FTE) Number of laboratories 170 225 >800 >800 Over 4x (year-end) Number of countries

  10. Slide 10: Exceptional Business Performance: Strong revenue growth

    Exceptional Business Performance Strong revenue growth Illustration of Eurofins’ historical revenue growth CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofin

  11. Slide 11: Business line description

    Eurofins is also present in several high growth Life Sciences markets which are critical for battling the COVID-19 pandemic ▪ Probes, primers and positive controls are Oligonucleotides Production and In Vitro Diagnostic (IVD) products key components required for COVID-19 Next Generation Sequencing (

  12. Slide 12: Life Sciences and IVD products to fight the COVID-19 pandemic

    Life Sciences and In Vitro Diagnostic (IVD) products to fight the COVID-19 pandemic Eurofins Technologies • Novatype RT-PCR – testing for fast variant identification SARS-CoV-2 may remain viable on different surfaces for up to ✓ Detect & ID RT-PCR assay, clinically validated for detecting variants s

  13. Slide 13: COVID-19 related business developments: innovation and product launches

    COVID-19 related business developments: innovation and product launches • GSD NovaPrime®, successfully validated for pharynx gargle and saliva samples • GSD NovaLisa®, a quantitative antibody ELISA kit to measure immune response to COVID-19 and vaccines ➢ CE marked serological assay ➢ Supports vacci

  14. Slide 14: COVID-19 related business developments: SAFER@WORK

    COVID-19 related business developments: SAFER@WORK™ • Through its SAFER@WORK™ programmes, Eurofins continues to enable many industries to sustain or re-start operations • Over 3,200 SAFER@WORK™ contracts with potential revenues of up to EUR 550m, signed or in final stage, across 36 countries • Signi

  15. Slide 15: II. Market & Strategic Positioning

    II. Market & Strategic Positioning CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 15

  16. Slide 16: Drivers for high long-term above GDP market growth

    Drivers for high long-term above GDP market growth Secular Underlying General Market Drivers Laboratory Market Drivers Fundamentals Demand for safe pharmaceuticals, Increasing wealth Consumer quality food and clean environment and quality of Life expectations for protection Consolidation of the frag

  17. Slide 17: Building leadership positions in an industry with significant network effects

    Building leadership positions in an industry with significant network effects and competitive advantage for the market leader ▪ High level of investment and innovation required to build and efficiently run a network of High barriers to modern laboratories (buildings, equipment, IT infrastructure and

  18. Slide 18: Building leadership positions with attractive and resilient organic growth

    Building leadership positions in an industry with attractive and resilient organic growth characteristics ▪ Market Structural growth: est. ~1.5-2x Gross Domestic Product (GDP) growth, globalisation, urbanisation, increasing need and demand for a healthier life and safer environment. Testing is the m

  19. Slide 19: Eurofins is the leader in most of its markets

    Eurofins is the leader in most of its markets and continues to build global & local leadership positions* in markets where scale matters New Markets 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Denmark: Food and Environment Testing Sweden, Norwa

  20. Slide 20: Majority of revenues come from markets with global leadership positions

    Overall, a large majority of Eurofins’ revenues come from markets where the Group has established global leadership positions Business Line Global leadership position Food & Feed testing ✓ These global Environment testing ✓ leadership positions are Clinical Diagnostics the basis to BioPharma Product

  21. Slide 21: Innovative testing technologies developed in 2020 (1/2)

    Innovative testing technologies developed in 2020 (1/2) • We believe we are uniquely positioned to derive new scientific meaning for years to come. We have: ✓ Capabilities in Environment, Food, Pharma and Clinical, reinforcing each other ✓ A unique fully digitised hub and spoke laboratory infrastruc

  22. Slide 22: Innovative testing technologies developed in 2020 (2/2)

    Innovative testing technologies developed in 2020 (2/2) o Food and Feed Testing Services: ✓ World’s first official method for the identification of fructans certified by the AOAC and ISO bodies ✓ New accredited method for authenticating products containing agave syrup and inulin ✓ Novel full-service

  23. Slide 23: Eurofins' strategy aims at building long lasting competitive advantage

    Eurofins’ strategy aims at building long lasting competitive advantage in very attractive markets Leading technology Quality of customer service ▪ Competence Centres & R&D activities ▪ Extensive expertise in local regulations for all major markets, and one-stop contact for compliance in multiple cou

  24. Slide 24: III. Commitment to ESG

    III. Commitment to ESG CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 24

  25. Slide 25: Our Businesses are ESG positive

    Our Businesses are ESG positive • We help improve health outcomes, ensure food safety and protect the environment • E.g., our Environment, Food and Feed Laboratories: ✓ Assess safety of the whole water cycle and analyse waste toxicity ✓ Monitor air pollution and soil quality ✓ Contribute to developi

  26. Slide 26: We are an ESG enabler for our clients

    We are an ESG enabler for our clients • We help our clients improve their ESG measurement and monitoring • Our world-leading, multidisciplinary expertise in laboratory testing and monitoring directly promotes human safety and environmental protection, including: ✓ Food Quality and Integrity ✓ Enviro

  27. Slide 27: Contribution to United Nations Sustainable Development Goals

    Eurofins is positively contributing to 16 of 17 United Nations Sustainable Development Goals (UNSDGs) Testing for Food & Feed Testing Environment Testing Clinical Diagnostics Pharma / Biotech / Agrosciences ESG Positive Contribution • Development of biological crop • Food and feed testing to support

  28. Slide 28: ESG Roadmap Key Highlights

    Our ongoing ESG commitment Environment Social Governance Commitment to achieve Carbon • Significant investment in • 2 new independent directors neutrality by 2025: training and talent appointed at the AGM 2021 • Launch a carbon footprint development with improvement bringing the total to 5 reduction

  29. Slide 29: Global Equality Driving Excellence Initiative: 2020 Achievements and 2021 Goals

    Global Equality Driving Excellence Initiative (EDE): 2020 Achievements and 2021 Goals 2020 achievements 2021 goals Increased Global Equality Ambassador Equality Targets in Leadership Expanded Regional EDE Female Leadership Council (33 members) Performance encouraging YOY Council Meetings Jan-20 Jan-

  30. Slide 30: IV. Finance & Outlook

    IV. Finance & Outlook CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 30

  31. Slide 31: Key financial highlights

    Key financial highlights Revenue Adjusted2 EBITDA3 Adjusted2 EBITDA3 Margin EUR 5.4bn ▲19%1 EUR 1,413m ▲52%1 26.0% ▲560bps1 Free Cash Flow to the Firm4 Net debt/EBITDA 5 Adjusted2 EPS6 EUR 873m ▲144%1 EUR 3.63 1.6x ▼1.6x1 ▲107%1 162% cash conversion7 per share 1 Year on year variation – 2020 vs 2019

  32. Slide 32: Q1 2021 - Key financial highlights

    Q1 2021 - Key financial highlights Key Highlights • Strong revenues in Q1 of EUR 1,614m, +41.3% year-on-year, despite a foreign exchange headwind of -3.7% (Q1 2021 vs. Q1 2020 average FX rates) • Very strong organic revenue growth1 of 44.3% in Q1 2021 reflecting the significant Revenue, EUR m contri

  33. Slide 33: Very strong results, ahead of the Group's most recent objectives

    Very strong results in terms of revenues and margin, ahead of the Group’s most recent objectives Full Year 2020 Full Year 2019 Key Highlights +/- Δ +/- Δ Adjusted1 SDIs2 Reported Adjusted1 SDIs2 Reported Adjusted Reported • Very strong revenue growth in Results Results Results Results Results Result

  34. Slide 34: Net working capital intensity improved in FY 2020

    Net working capital intensity improved in FY 2020 NWC intensity 2.6% Key Highlights 2.3% 5.3% 5.3% 1.6% • Net working capital intensity Inventory decreased by 80bps in 157 FY20 to 4.5% of revenues. 124 79 The absolute change in NWC was largely driven by FY 2019 H1 2020 FY 2020 the impact of COVID-19

  35. Slide 35: Consistent capital investments in laboratories and IT solutions

    Consistent capital investments to develop a unique network of laboratories and state-of-the-art IT solutions Net Capex (EUR m) Infrastructure1 Capex (EUR m) IT 2 Capex (EUR m) Key Highlights • Net Capex/Revenues ratio fell to Real Estate 6.4% of Group’s revenues in FY20 vs. 7.0% in FY 2019 as the Gr

  36. Slide 36: Very solid liquidity position and significant reduction in leverage

    Very solid liquidity position at year end and significant reduction in leverage Leverage* Debt maturity profile (EUR m) Key Highlights • Strong cash flow generation and 3.4x the successful equity issuance 3.2x (EUR 535m) in May 2020 driving 300 significant reduction in net debt, from EUR 3,245m to E

  37. Slide 37: Outlook: objectives remain unchanged at this time

    Outlook: objectives remain unchanged at this time Increasingly likely that 2021 objectives will be materially exceeded and significant levels of testing for COVID-19 may continue well beyond Q1 2021. The exact impact and timing of vaccination, new variants of concern and public health policy decisio

  38. Slide 38: Conclusion: our sustainable competitive advantage

    Conclusion: our sustainable competitive advantage Best in class technology and quality give best brand protection High-growth, non-cyclical markets driven by secular mega- trends N° 1 or 2 worldwide in most business lines Advancing globalisation but with very few global testing Operating in more tha

  39. Slide 39: V. Contemplated transaction

    V. Contemplated transaction CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 39

  40. Slide 40: Rationale and Calendar

    Rationale and Calendar The rationale for the contemplated transaction is threefold: 1) Refinance shorter dated senior bonds into a new 10y bond to extend our maturity profile 2) Optimize future interest expense, refinancing with a lower cost of debt 3) Potentially further reducing gross debt by targ

  41. Slide 41: New issue key terms and conditions

    New issue key terms and conditions Issuer Eurofins Scientific S.E. Status Senior unsecured Form of the notes Regulation S, bearer notes Issue rating Baa3 (Moody’s) / BBB- (Fitch) Issue size EUR Benchmark Coupon Fixed rate payable annually in arrear, Actual/Actual (ICMA) Maturity 10-year Denomination

  42. Slide 42: Tender offers summary

    Tender offers summary EUR 500m 3.375% bonds due 30 Jan 2023 EUR 650m 2.125% bonds due 25 July 2024 EUR 600m 3.750% bonds due 17 July 2026 Description (the ”2023 Bonds”) (the ”2024 Bonds”) (the ”2026 Bonds”) Issuer Eurofins Scientific S.E. (French Branch) Eurofins Scientific S.E. (French Branch) Euro

  43. Slide 43: Appendix

    Appendix CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 43

  44. Slide 44: Consolidated Income Statement

    Consolidated Income Statement For the year ended 31 December 2020 2020 2019 Separately Separately EUR Millions Adjusted results Reported results Adjusted results Reported results disclosed items disclosed items Revenues 5,438.8 - 5,438.8 4,562.8 - 4,562.8 Operating costs, net -4,026.1 -61.8 -4,087.9

  45. Slide 45: Consolidated Balance Sheet

    Consolidated Balance Sheet 31 December 31 December 31 December 31 December EUR Millions EUR Millions 2020 2019 2020 2019 Property, plant and equipment 1,574.9 1,593.5 Share capital 1.9 1.8 Goodwill 3,524.1 3,608.8 Treasury Shares - -0.2 Other intangible assets 825.1 918.2 Hybrid capital 1,000.0 1,00

  46. Slide 46: Consolidated Cash Flow Statement

    Consolidated Cash Flow Statement (2020 figures) For the year ended 31 December 2020 EUR Millions 2020 2019 EUR Millions 2020 2019 Cash flows from operating activities Cash flows from financing activities Profit before income taxes 694.4 271.5 Proceeds from issuance of share capital 564.8 23.4 Deprec

  47. Slide 47: Definitions / Alternative Performance Measures (APMs)

    Definitions / Alternative Performance Measures (APMs) Eurofins is providing in the consolidated financial statements certain alternative performance measures (non-IFRS information). APMs used in the Consolidated Income Statement Adjusted results – reflect the ongoing performance of the mature and re

Eurofins Scientific — Debt Investor Presentation (May 2021) on 6ix